# Abbott Laboratories (ABT) — Stock CV

Abbott Laboratories is a $173B healthcare company. Revenue grew 8.1% over the last year, it keeps 12¢ of every dollar of sales as profit, and its net debt equals ~0.1 years of free cash flow. It trades at 31.8× earnings — around the middle of its own history.

> Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs.

## Identity

- **Ticker**: ABT
- **Sector**: Healthcare
- **Industry**: Medical Devices
- **Headquarters**: ABBOTT PARK, IL
- **Employees**: 115 000
- **Website**: https://www.abbott.com
- **Market cap**: $173B
- **Last price**: $99.78
- **Financial profile**: Solid

## Vitals (TTM)

- **Revenue**: $46.6B
- **Net income**: $5.42B
- **Free cash flow**: $7.82B
- **Net debt**: $957M
- **P/E**: 31.8
- **Revenue growth (YoY)**: 8.1%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 56 |
| Growth | 43 |
| Profitability | 64 |
| Health | 75 |
| Quality | 87 |
| Moat | 62 |

## Qualifications (beginner checklist) — 10 of 11 passed

- [x] Revenue growing — +8.1% YoY
- [x] Profitable — $5.42B TTM
- [ ] Profit growing — -1.7% YoY
- [x] Generates cash — $7.82B TTM
- [x] Debt under control — ~0.1y of cash flow to repay
- [x] Established company — $173B market cap
- [x] Not printing shares — -2.1% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [x] Financially stable — Altman Z 2.8 — grey
- [x] Pays a dividend — yield 2.47%
- [x] Valuation not extreme — P/E 31.8

## Experience (career milestones)

- **2025** — Abbott announced an agreement to acquire Exact Sciences Corp
- **FY2024** — Best year on record: $13.4B net income
- **2020** — The Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve…
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $10B: $20.9B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2014** — It was announced that Abbott would acquire the holding company Kalo Pharma Internacional S.L
- **2010** — Abbott acquired the pharmaceuticals unit of Solvay S.A
- **2009** — Abbott acquired Advanced Medical Optics of Santa Ana, California, selling it to Johnson & Johnson in 2017
- **2007** — Abbott acquired Kos Pharmaceuticals for $3.7 billion in cash
- **2007** — Abbott's Ross Products was renamed Abbott Nutrition in 2007
- **2004** — Abbott completed the corporate spin-off of Hospira, its hospital products division
- **2004** — It acquired TheraSense, a diabetes-care company, which it merged with its MediSense division to become…
- **2001** — The company acquired Knoll, the pharmaceutical division of BASF, for $6.9 billion

## Strengths

- High gross margin (56.8%)
- Strong cash conversion — FCF is 16.8% of revenue
- Interest covered 63.7× by operating earnings
- Piotroski F-Score 7/9 — fundamentally strong checklist

## Watch-outs

- None stand out in the data.

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $43.1B | $7.07B | $8.65B |
| FY2022 | $43.7B | $6.93B | $7.80B |
| FY2023 | $40.1B | $5.72B | $5.06B |
| FY2024 | $42.0B | $13.4B | $6.35B |
| FY2025 | $44.3B | $6.52B | $7.39B |

---

Source: https://stockcv.com/ABT — derived from company filings; may be delayed or incomplete. Information, not investment advice.